The once-daily topical cream for the treatment of atopic dermatitis (AD) has demonstrated positive topline results in 2 phase 3 studies in adults and children aged 2 years and up. According to Dermavant, a supplemental new drug application (sNDA) filed with the FDA is anticipated in Q1 of 2024.
Ritlecitinib could be a suitable treatment option for alopecia areata patients aged 12 years and older following positive results from a recent trial.
Roflumilast is a once-daily, topical phosphodiesterase type 4 (PDE4) inhibitor under development for treatment of inflammatory dermatoses, focusing on the hair-bearing areas including the face, scalp, and trunk.
Research was conducted on the paradoxical effect of TNF inhibitor–induced psoriasiform eruption in children and adolescents treated with inhibitors for conditions other than psoriasis.
With Juvenile spring eruption (JSE), exposure to sunlight in early spring or summer results in a papulovesicular rash that usually resolves within 1 to 2 weeks.
New data from a study in Egypt suggests that several key factors contribute to some of the negative impacts of psoriasis on mothers of children with the skin condition.
A recent analysis showed that a combination treatment made of phosphate, adapalene, and benzoyl peroxide known as IDP-126 was well-tolerated and effective in pediatric participants with acne.
In identical phase 3 trials, roflumilast demonstrated topline positive results, reducing itch in children and adults with mild to moderate AD.
In a phase 3 clinical trial, dupilumab met both its primary and key secondary endpoints, demonstrating efficacy as a potential treatment for atopic hand and foot dermatitis.
A recent study indicated that lebrikizumab treatment for 16 weeks was effective for adolescents and adults with moderate-to-severe atopic dermatitis.
Results from a recent phase 3 clinical trial demonstrated topline safety and efficacy results for tapinarof cream, 1% (VTAMA; Dermavant) as a potential treatment for atopic dermatitis in patients 2 years and older.
Following positive results from a phase 3 clinical trial, the FDA has accepted a New Drug Application for berdazimer gel, 10.3% (Novan) for treating patients with molluscum contagiosum.
A supplemental Biologics License Application has been accepted by the FDA for treating adolescents and adults with chronic spontaneous urticaria.
In data presented at the AAAAI annual conference, 5 common contact dermatitis-causing allergens were identified, emphasizing the importance of patch testing.
A New Drug Application has been submitted to the FDA for potential approval of roflumilast foam 0.3% for the treatment of seborrheic dermatitis in adults and adolescents.
A research letter addresses the challenges of accurately diagnosing asthma, atopic eczema, and allergic rhinitis in children under 5 years old and the use of Read codes and prescription data as diagnostic criteria.
An interview with Victoria Barrio, MD, and Fabiana Castro Porto Silva Lopes, MD, about the Society for Pediatric Dermatology and its efforts to address diversity in the dermatology field.
A 16-year-old boy with developmental delay and intellectual disability developed dramatic chronic wrinkling of his scalp over a year ago. The lesions were persistent but not symptomatic. What's the diagnosis?
A healthy 17-year-old girl with inflammatory acne had failed to respond to topical tretinoin, benzoyl peroxide, and oral minocycline. What's the diagnosis?
Arcutis Biotherapeutics, Inc has submitted a supplemental New Drug Application for roflumilast cream (ZORYVE) to the US Food and Drug Administration for treatment of plaque psoriasis in children aged 2 to 11 years.
A recent article highlighted multiple therapies for treating atopic dermatitis, including many which do not require a prescription.
A recent article highlighted multiple forms of treatment for atopic dermatitis, detailing their benefits and adverse events.
Adults with atopic dermatitis saw improved symptoms when taking dupilumab compared to placebo, regardless of the age when they first presented with the condition.
Pediatric care requires understanding, not only of the disease impact, but also its presentation and management in children.
This brain imaging study was the first to look at the position of depression and systemic inflammation in brain measures while including the largest sample of patients with psoriasis to date.
